Status:
RECRUITING
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
Lead Sponsor:
Peking University Cancer Hospital & Institute
Conditions:
Solid Tumor
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
The objective of the study is to construct a noninvasive approach 68Ga-ACN376 PET/CT to detect the CLDN18.2 expression of tumor lesions in patients with Solid tumors and to identify patients benefitin...
Eligibility Criteria
Inclusion
- 1\. Aged \>18 years old; ECOG 0 or 1;
- 2\. Patients with solid tumors;
- 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);
- 4\. life expectancy \>=12 weeks.
Exclusion
- 1\. Significant hepatic or renal dysfunction;
- 2\. Is pregnant or ready to pregnant;
- 3\. Cannot keep their states for half an hour;
- 4\. Refusal to join the clinical study;
- 5\. Suffering from claustrophobia or other mental diseases;
- 6\. Any other situation that researchers think it is not suitable to participate in the experiment.
Key Trial Info
Start Date :
June 23 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT05436093
Start Date
June 23 2022
End Date
December 1 2024
Last Update
January 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing cancer hospital
Beijing, Beijing Municipality, China, 100142